How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? Within classes are there any criteria by which you select a specific product?
Community PollStarted
How are you generally sequencing cellular therapies for relapsed DLBCL post Auto-SCT in a fit patient?
36 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Memorial Sloan Kettering
Answered on
If a patient relapses after an autologous stem cell transplant and is a candidate for CAR T-cell therapy, I would proceed with CAR T-cell therapy given longer follow up compared to bispecific antibodies, and thus a portion of the patient can achieve a durable complete response. For patients that rel...
Join for free or sign in to see the full answer